Supplementary Table 1 The primary and secondary outcomes estimated in all patients taking aspirin.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Outcome** | **Aspirin** | **Model** | **HR[95% CI]** | **p-value** |
| 30-day mortality，n(%) |  |  |  |  |
| YES | 1403(14.0) | Crude | 0.53 [0.50, 0.57] | <0.001 |
| NO | 8585(86.0) | Adjusted\* | 0.54 [0.50, 0.59] | <0.001 |
| 90-day mortality，n(%) |  |  |  |  |
| YES | 1978(19.8) | Crude | 0.59 [0.55, 0.62] | <0.001 |
| NO | 8009(80.2) | Adjusted\* | 0.59 [0.55, 0.64] | <0.001 |
| 180-day mortality，n(%) |  |  |  |  |
| YES | 2360(23.6) | Crude | 0.62 [0.59, 0.66] | <0.001 |
| NO | 7628(76.4) | Adjusted\* | 0.62 [0.58, 0.66] | <0.001 |
|  |  |  | **OR[95% CI]** |  |
| Transfusion，n(%) |  |  |  |  |
| YES | 3723(37.3) | Crude | 1.25 [1.17, 1.33] | <0.001 |
| NO | 6265(62.7) | Adjusted\* | 1.25 [1.13, 1.38] | <0.001 |
| ICH，n(%) |  |  |  |  |
| YES | 148(1.5) | Crude | 0.45 [0.37, 0.55] | <0.001 |
| NO | 9840(98.5) | Adjusted\* | 0.51 [0.39, 0.65] | <0.001 |
| GI Bleeding，n(%) |  |  |  |  |
| YES | 84(0.8) | Crude | 0.61 [0.46, 0.80] | <0.001 |
| NO | 9904(99.2) | Adjusted\* | 0.60 [0.42, 0.86] | 0.006 |

GI Bleeding, gastrointestinal bleeding; ICH, intracranial hemorrhage. HR, hazard ratio; OR, odds ratio; CI, confidence interval;\*Adjusted: gender, age, race, hemoglobin, WBC, platelets, anion gap, bicarbonate, bun, chloride, creatinine, sodium, potassium, heart rate, mean blood pressure, respiratory rate, temperature, SpO2, myocardial infarct, congestive heart failure, cerebrovascular disease, mild liver disease, severe liver disease, hypertension, diabetes mellitus, chronic kidney disease, glucose, sepsis, paraplegia, malignant cancer, dementia, Charlson comorbidity index, SOFA, SAPSII, GCS scores, invasive mechanical ventilation, renal replacement therapy, AKI stage, first care unit, vasopressors use.